CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 …
Read more here:
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …